Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / DBCV 1.500%11/1
-
Market price (% of par)
-
132.06%
-
Total 13F principal
-
$544,016,000
-
Principal change
-
-$12,705,000
-
Total reported market value
-
$719,711,018
-
Number of holders
-
40
-
Value change
-
-$16,204,729
-
Number of buys
-
18
-
Number of sells
-
15
Institutional Holders of SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 as of Q2 2021
As of 30 Jun 2021,
SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 was held by
40 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$544,016,000
in principal (par value) of the bond.
The largest 10 bondholders included
DeepCurrents Investment Group LLC, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, BAKER BROS. ADVISORS LP, Verition Fund Management LLC, CALAMOS ADVISORS LLC, BANK OF AMERICA CORP /DE/, and Linden Advisors LP.
This page lists
40
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.